Outcomes by Minimum Inhibitory Concentrations for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials [Susceptibility]

This pooled analysis evaluated the relationship of isavuconazole and voriconazole minimum inhibitory concentrations (MICs) of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with MICs ≥16 µg/mL, but there was no relationship in cases where the MIC was <16 µg/mL with clinical outcomes for either drug.

https://ift.tt/2qe8xmC